Debiopharm

Debiopharm Group (Debiopharm) is a family-owned biopharmaceutical group of companies active in drug development and manufacturing of proprietary drugs, diagnostics, and investments,[1] headquartered in Lausanne, Switzerland. It was founded in 1979 by Rolland-Yves Mauvernay.[2]

Debiopharm Group
TypeSociété Anonyme
IndustryBiopharmaceutical
FoundedLausanne, Switzerland (1979)
FounderDr Rolland-Yves Mauvernay (1922-2017)
HeadquartersLausanne, Switzerland
Area served
Worldwide
Key people
  • Thierry Mauvernay (President)
  • Bertrand Ducrey (CEO Debiopharm International SA)
  • Cédric Sager (CEO Debiopharm Research & Manufacturing SA)
  • Valérie Calvayrac (CEO Debiopharm Investment SA)
Products
RevenueUS$ 25 billion
Ownerfamily-owned
Number of employees
420
Websitewww.debiopharm.com

Subsidiaries

The group works through its subsidiaries:[3]

  • Debiopharm International SA, which in-licenses product candidates or technologies, develops them, and then licenses them to third parties for commercialization;[4]
  • Debiopharm Research and Manufacturing SA, which provides contract manufacturing and contract research services to Debiopharm;[5]
  • Debiopharm Investment SA, which manages the group's money and invests in real estate and in other companies; and[6]
  • Debiopharm Diagnostics SA, which invests in diagnostics companies.[7]

As of 2010 two drugs had reached the market through its efforts: oxaliplatin for the treatment of cancer, and depot formulations of triptorelin, a gonadotropin-releasing hormone agonist that is approved to treat advanced prostate cancer.[8]

In 2017, Debiopharm acquired a phase 2 drug candidate from ImmunoGen that intends to target Non-Hodgkin lymphoma.[9]

References
  1. Group, Debiopharm. "Debiopharm Group™ to Acquire Products or Companies to Expand Activities at Manufacturing Facility in Martigny (Valais, Switzerland)". www.prnewswire.com. Retrieved 2020-04-10.
  2. Bloomberg profile: Debiopharm Group. Page accessed May 12, 2016
  3. Frost & Sullivan Nov 25 2010 Movers & Shakers Interview with Maurice Wagner, Debiopharm Group
  4. Bloomberg profile: Debiopharm International. Page accessed May 12, 2016
  5. Bernard Tappy for In Vivo Magazine. 2013 Debiopharm Research and Manufacturing SA.
  6. Swiss Private Equity & Corporate Finance Association Debiopharm Investment SA Page accessed May 12, 2016
  7. Bloomberg profile: Debiopharm Diagnostics. Page accessed May 12, 2016
  8. "Triptorelin". drugs.com. Retrieved 11 November 2016.
  9. Taylor, Nick (24 May 2017). "Debiopharm buys ImmunoGen ADC to grow cancer pipeline". Fierce Biotech. Retrieved 23 June 2018.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.